Hyperion Therapeutics, Inc Information

Hyperion Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology. Hyperion is currently developing Ravicti™ (glycerol phenylbutyrate), formerly known as HPN-100, for both urea cycle disorders (UCD) and hepatic encephalopathy (HE). Hyperion acquired the worldwide rights to Ravicti from Ucyclyd Pharma, Inc, a wholly owned subsidiary of Medicis Pharmaceutical Corporation in March 2012. Hyperion also has an option to acquire, in the first half of 2013 for a pre-negotiated price, Ucyclyd’s worldwide rights to BUPHENYL® and, subject to certain conditions, AMMONUL®. Hyperion is led by a seasoned executive team with extensive experience developing and commercializing specialty pharmaceutical products.